Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Novocure < Previous 1 2 3 Next > Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies August 29, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer August 28, 2023 From Novocure Via Business Wire Tickers NVCR Novocure to Participate in Upcoming Investor Conferences August 25, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Reports Second Quarter 2023 Financial Results July 27, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer July 21, 2023 From Novocure Via Business Wire Tickers NVCR Novocure to Report Second Quarter 2023 Financial Results July 03, 2023 From Novocure Via Business Wire Tickers NVCR LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies June 06, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education June 01, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Reports First Quarter 2023 Financial Results May 04, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023 April 14, 2023 From Novocure Via Business Wire Tickers NVCR Novocure to Report First Quarter 2023 Financial Results April 03, 2023 From Novocure Via Business Wire Tickers NVCR Kristin Stafford Joins Novocure Board of Directors March 29, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program March 16, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France March 01, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer March 01, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update February 23, 2023 From Novocure Via Business Wire Tickers NVCR Allyson J. Ocean, M.D., Joins Novocure Board of Directors February 23, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer February 15, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Organizational Changes to Prepare for Future Growth January 19, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update January 09, 2023 From Novocure Via Business Wire Tickers NVCR Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint January 05, 2023 From Novocure Via Business Wire Tickers NVCR Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference December 27, 2022 From Novocure Via Business Wire Tickers NVCR Novocure’s Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma November 29, 2022 From Novocure Via Business Wire Tickers NVCR Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference November 23, 2022 From Novocure Via Business Wire Tickers NVCR Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting November 17, 2022 From Novocure Via Business Wire Tickers NVCR Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada November 15, 2022 From Novocure Via Business Wire Tickers NVCR Novocure Secures CE Mark for New Array November 11, 2022 From Novocure Via Business Wire Tickers NVCR Novocure Reports Third Quarter 2022 Financial Results October 27, 2022 From Novocure Via Business Wire Tickers NVCR Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting October 21, 2022 From Novocure Via Business Wire Tickers NVCR < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.